Human Chorionic Gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone > 300 ng/dL

V. Madhusoodanan, P. Patel, T. Lima, Jabez C Gondokusumo, E. Lo, N. Thirumavalavan, L. Lipshultz, R. Ramasamy
{"title":"Human Chorionic Gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone > 300 ng/dL","authors":"V. Madhusoodanan, P. Patel, T. Lima, Jabez C Gondokusumo, E. Lo, N. Thirumavalavan, L. Lipshultz, R. Ramasamy","doi":"10.1590/S1677-5538.IBJU.2019.0132","DOIUrl":null,"url":null,"abstract":"ABSTRACT Purpose The 2018 American Urological Association guidelines on the Evaluation and Management of Testosterone Deficiency recommended that 300 ng/dL be used as the threshold for prescribing testosterone replacement therapy (TRT). However, it is not uncommon for men to present with signs and symptoms of testosterone deficiency, despite having testosterone levels greater than 300 ng/dL. There exists scant literature regarding the use of hCG monotherapy for the treatment of hypogonadism in men not interested in fertility. We sought to evaluate serum testosterone response and duration of therapy of hCG monotherapy for men with symptoms of hypogonadism, but total testosterone levels > 300 ng/dL. Materials and Methods We performed a multi-institutional retrospective case series of men receiving hCG monotherapy for symptomatic hypogonadism. We evaluated patient age, treatment indication, hCG dosage, past medical history, physical exam findings and serum testosterone and gonadotropins before and after therapy. Descriptive analysis was performed and Mann Whitney U Test was utilized for statistical analysis. Results Of the 20 men included in the study, treatment indications included low libido (45%), lack of energy (50%), and erectile dysfunction (45%). Mean testosterone improved by 49.9% from a baseline of 362 ng/dL (SD 158) to 519.8 ng/dL (SD 265.6), (p=0.006). Median duration of therapy was 8 months (SD 5 months). Fifty percent of patients reported symptom improvement. Conclusions Treatment of hypogonadal symptoms with hCG for men who have a baseline testosterone level > 300 ng/dL appears to be safe and efficacious with no adverse events.","PeriodicalId":13674,"journal":{"name":"International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology","volume":"56 1","pages":"1008 - 1012"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S1677-5538.IBJU.2019.0132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

ABSTRACT Purpose The 2018 American Urological Association guidelines on the Evaluation and Management of Testosterone Deficiency recommended that 300 ng/dL be used as the threshold for prescribing testosterone replacement therapy (TRT). However, it is not uncommon for men to present with signs and symptoms of testosterone deficiency, despite having testosterone levels greater than 300 ng/dL. There exists scant literature regarding the use of hCG monotherapy for the treatment of hypogonadism in men not interested in fertility. We sought to evaluate serum testosterone response and duration of therapy of hCG monotherapy for men with symptoms of hypogonadism, but total testosterone levels > 300 ng/dL. Materials and Methods We performed a multi-institutional retrospective case series of men receiving hCG monotherapy for symptomatic hypogonadism. We evaluated patient age, treatment indication, hCG dosage, past medical history, physical exam findings and serum testosterone and gonadotropins before and after therapy. Descriptive analysis was performed and Mann Whitney U Test was utilized for statistical analysis. Results Of the 20 men included in the study, treatment indications included low libido (45%), lack of energy (50%), and erectile dysfunction (45%). Mean testosterone improved by 49.9% from a baseline of 362 ng/dL (SD 158) to 519.8 ng/dL (SD 265.6), (p=0.006). Median duration of therapy was 8 months (SD 5 months). Fifty percent of patients reported symptom improvement. Conclusions Treatment of hypogonadal symptoms with hCG for men who have a baseline testosterone level > 300 ng/dL appears to be safe and efficacious with no adverse events.
人绒毛膜促性腺激素单药治疗总睾酮> 300 ng/dL男性性腺功能减退症状
2018年美国泌尿学会关于睾酮缺乏评估和管理的指南建议将300 ng/dL作为处方睾酮替代疗法(TRT)的阈值。然而,男性表现出睾酮缺乏的体征和症状并不罕见,尽管他们的睾酮水平高于300纳克/分升。关于使用hCG单一疗法治疗对生育不感兴趣的男性性腺功能减退的文献很少。我们试图评估有性腺功能减退症状但总睾酮水平> 300 ng/dL的男性的血清睾酮反应和hCG单药治疗的持续时间。材料和方法我们对接受hCG单药治疗症状性性腺功能减退的男性进行了多机构回顾性病例系列研究。我们评估了患者的年龄、治疗适应症、hCG剂量、既往病史、体检结果以及治疗前后的血清睾酮和促性腺激素。采用描述性分析,Mann Whitney U检验进行统计分析。结果在纳入研究的20名男性中,治疗指征包括性欲低下(45%)、精力不足(50%)和勃起功能障碍(45%)。平均睾酮水平从基线362 ng/dL (SD 158)提高到519.8 ng/dL (SD 265.6),提高了49.9% (p=0.006)。治疗中位持续时间为8个月(SD为5个月)。50%的患者报告症状有所改善。结论:hCG治疗基线睾酮水平> 300 ng/dL的男性性腺功能减退症状安全有效,无不良事件发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信